Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
Anna Myriam PerroneCamelia Alexandra CoadăGloria RavegniniAntonio De LeoGiuseppe DamianoEugenia De CrescenzoMarco TeseiStella Di ConstanzoLucia GenovesiDaniela RubinoClaudio ZamagniPierandrea De IacoPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)
Increasing the number of neoadjuvant chemotherapy cycles does not worsen patient outcomes if complete resection is achieved. Nevertheless, additional prospective trials are necessary to establish the optimum number of neoadjuvant chemotherapy cycles.